Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
← catalyst calendarNCT06066580 · readout ≤ 1,654 d
Sponsored by Edgewise Therapeutics, Inc. (industry) · EWTX — their whole pipeline →. With Medpace, Inc..
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
260estimated
Sites
46
Countries
Belgium, Denmark, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-02 | actual | When the study began enrolling |
| Primary completion | Feb 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Becker Muscular Dystrophy
Intervention
- Drug: Sevasemten
Primary outcomes
what the primary-completion date above is the date OFNumber of adverse events in those treated with sevasemten
measured 55 Months
Severity of adverse events in those treated with sevasemten
measured 55 Months
Permalink · EWTX's whole pipeline · Catalyst calendar · Every registered study · What changed